Pfizer Inc/stats, details
Contents
- 1 Detailed Information
- 2 Basic Information
- 2.1 HQ Contact information
- 2.2 Country of incorporation
- 2.3 Ownership status
- 2.4 Primary industry sector
- 2.5 2007 Primary Industry Ranking
- 2.6 Number of employees worldwide
- 2.7 Chief executive officer
- 2.8 Financial information
- 2.9 Books on company
- 2.10 Sources
- 2.11 External resources
- 2.12 External articles
Detailed Information
Business Structure
Lines of business
Human Healthcare (prescription drug products)
Animal Healthcare
Units/subsidiaries [1]
- Embrex
- Warner-Lambert
- Parke-Davis
- Animal Health Group
- Pfizer Austria
- Pfizer Canada
- Pfizer Denmark
- Pfizer Europe
- Pfizer Global Research and Development
- Pfizer Ireland
- Pfizer Italy
- Pfizer Japan
- Pfizer Malaysia - Singapore
- Pfizer Pharmaceuticals Group
- Pfizer Spain
- Pfizer Sweden
- Pfizer Taiwan
- Pfizer Turkey
Major Acquisitions
Warner-Lambert, February 2000
Pharmacia Corporation, April 2003
Esperion Therapeutics, February 2004
Vicuron Pharmaceutical, September 2005
Major Products By Patent Expiration Date
Zithromaxin(2005)
Zoloft(2006)
Norvasc (2007)
Zyrtec (2007)
Camptosar (2008)
Aricept (2010)
Lipitor (2010)
Viagra (2012)
Celebrex (2014)
Lyrica (2018)
Sutent (2021)
Wholesalers
2006: Percent of Total Revenue
- McKesson Inc 20%
- Cardinal Health Inc 13%
- AmerisourcesBergen Corp 11%
Competitors
Merck
Sanofi-Aventis
GlaxoSmithKline
Bristol-Myers Squibb
Creditors
Geographic scope
Countries of operation
Research and Development:
- USA
- China
- England
- France
- Japan
Veterinary Medicine Research:
- Australia
Global Manufacturing:
- USA
- Brazil
- Belgium
- Germany
- Ireland
- Italy
- Mexico
- Puerto Rico
- Singapore
- Sweden
- United Kingdom
Breakdown of revenues[2]
2006: By Division
- 93.2% Pharmaceutical Division
- 4.8% Animal Health
By Geography
- US Sales: 53.4% ($25.8 billion)
- International Sales: 46.6% ($22.5 billion)
- Japan: 6.7%(of total revenue)
By Major Product:
- Lipitor $12.9 billion
- Norvasc $4.87 billion
- Zoloft $2.1 billion
- Celebrex $2.04 billiion
2005:
- 93.4% Pharmaceutical Division ($45 billion)
- 4.6% Animal Health
Breakdown of profits
Breakdown of assets
Board members & affiliations[3]
Jeffrey B. Kindler, Chairman of the Board
Alan G Levin, Chief Financial Officer
Loretta Cangialosi, Chief Accounting Officer
Dennis Ausiello
Michael S. Brown
M. Anthoy Burns
Robert N. Burt
W. Don Cornwell
William H. Gray III
- Former Congressman, Pennsylvania 2nd (1979-1991)
- Director of Dell
- Director of Prudecntial
- Director of JP Morgan Chase
Constance J. Horner
- Former Civil Rights Commissioner
William R. Howell
- Former CEO, JC Penney (1983-1997)
Stanley O. Ikenberry
- Director TIAA-CREF
- Former President, American Council on Education (1996-2001)
- Former President, University of Illinois (1979-1995)
George A. Lorch
- CEO of Armstrong
Henry A. McKinnell, former CEO, Pfizer (2001-2006)
- Chairman of PhRMA
- Director of Stanford Graduate School of Business Advisory Council
- Member Board of Trustees of NYC Public Library
Dana G. Mead
- Member of the Executive Compensation Committee
- retired CEO of Tenneco, Inc.
- Chairman, MIT Corporation
Ruth J. Simmons
- President, Brown University
- Former President of Smith College
- Director of Metropolitan Life
- Director of Goldman Sachs Group
- Director of Texas Instruments
Wiliam C. Steere, Jr., former CEO of Pfizer (1991-2001)
- Director of Connecticut Mutal Life Insurance
- Director of Texaco
Executive/director compensation
2006:
- Henry A. McKinnell: $12,968,829[4]
Date & venue of next AGM
Labor
98,000 worldwide
- 38,000 sales representatives
- 12,000 medical researchers[5]
- Plan to eliminate 10,000 employees by end of 2008[6]
- Includes a 20% reduction in European sales force
- Closing of manufacturing plants in Brooklyn, NY and Omaha, NB.
- Close research site in Michigan, Japan, and France
Domestic
Global
Basic Information
HQ Contact information
235 E. 42nd St.
New York, NY 10017
Phone: 212-573-2323
Fax: 212-573-7851
Web: http://www.pfizer.com
Country of incorporation
United States (Delaware)
Ownership status
Public
Primary industry sector
- Pharmaceuticals
- Animal Health
2007 Primary Industry Ranking
Fortune 500 Rank: 39 (2006, 31) [7]
Fortune Pharmaceutical Industry Rank: 2
Forbes 2000 Profit Rank: 7[8]
Financial Times Global 500: 17[9]
Number of employees worldwide
98,000
Chief executive officer
Jeffrey B. Kindler, 51
Financial information
Ticker symbol
PFE
Main exchanges
NYSE
Investor website
http://www.pfizer.com/investors
- Barclays Global Investors, 5.13%
- AXA, 3.21%
- State Street Corporation, 3.14%
- Vanguard Group, 2.94%
- Capital Research and Management, 2.14%
Total revenue
2006 Net Sales: $48,370,000,000
Net income
2006 Net Income: $19,337,000,000
Books on company
- Kanter, RM (ed). “Innovation: Breakthrough Thinking at 3M, DuPont, GE, Pfizer and Rubbermaid”, 1997.
- McKinnell, Hank. “A Call to Action”, 2005.
- Mines, S. “Pfizer: An Informal History”, 1978.
- Pratt, Edmund T. “Pfizer: Bringing Science to Life”, 1985.
- Reidy, Jamie. “Hard Sell: The Evolution of a Viagra Salesman”, 2005.
- Rodengen, Jeffrey. “The Legend of Pfizer”, 1999.
Sources
- ↑ http://www.mind-advertising.com/us/pfizer_us.htm
- ↑ http://pfizer.com/investors/sec_filings.jsp
- ↑ http://www.nndb.com/company/608/000053449
- ↑ http://www.aflcio.org/corporatewatch/paywatch/ceou/database.cfm?tkr=PFE&pg=1
- ↑ http://www.oneworldtrust.org/?display=Pfizer
- ↑ http://www.iht.com/articles/2007/01/22/business/pfizer.php
- ↑ http://money.cnn.com/magazines/fortune/fortune500/2007/snapshots/1042.html
- ↑ http://www.forbes.com/lists/2007/18/biz_07forbes2000_The-Global-2000_Prof.html
- ↑ http://www.ft.com/reports/ft5002007
- ↑ http://finance.yahoo.com/q/mh?s=PFE
External resources
Google Newsfeed on Pfizer
Pfizer OSHA Report
AFL-CIO Executive Paywatch
Oxfam Report on Pfizer
http://en.wikipedia.org/wiki/Pfizer
